Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer

NCT00113789 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
21
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Amgen